ArticleJournal of family & community medicine
Comparative risk of depressive disorder in patients with diabetic neuropathy treated with gabapentin versus duloxetine: Retrospective cohort study.
Article in Journal of family & community medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepressive disorders (DD) are highly prevalent in patients with diabetic neuropathy (DN), yet a little is known about how commonly used neuropathic agents, duloxetine and gabapentin, differentially influence psychiatric outcomes in this population. MATERIALS AND
methodsWe conducted a retrospective cohort analysis using the TriNetX electronic health record network containing patient data from more than 69 healthcare organizations, version v5.0, between January 2000 and December 2025. After propensity score matching, patients treated for diabetic neuropathy were grouped into balanced cohorts of 18,674 gabapentin-treated patients and 16,223 duloxetine-treated patients. The primary outcome was new-onset DD within 5 years following initiation of treatment. Risk estimates and survival analyses compared cohorts.
resultsPatients treated with duloxetine had a significantly higher 5-year risk of developing DD than those treated with gabapentin (16.3% vs. 14.8%; risk ratio 1.099, 95% confidence interval [CI]: 1.046-1.154). Kaplan-Meier analysis demonstrated a lower survival probability free from DD in the duloxetine group (83.7% vs. 85.2%), with a hazard ratio of 1.318 (95% CI 1.250-1.391,
conclusionIn this propensity score-matched real-world cohort, duloxetine was associated with a significantly higher, albeit small absolute risk of incident DD compared with gabapentin. These findings suggest a correlational association with the use of duloxetine and psychiatric risk in this specific patient population. This highlights possible consideration of psychiatric outcomes when treatments are selected for DN and also supports the need for future prospective studies to confirm causality and further evaluate the psychiatric effects of therapies for neuropathic pain.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.